Vol. 2 No. 3 (2022)
Reimbursement Recommendations

Somatrogon (Ngenla)

Published March 24, 2022

Key Messages

  • CADTH recommends that Ngenla should be reimbursed by public drug plans for the treatment of growth hormone deficiency if certain conditions are met.
  • Ngenla should only be covered to treat children who are at least 3 years of age, who did not reach puberty yet, and who are diagnosed with growth hormone deficiency.
  • Ngenla should only be reimbursed if prescribed by a pediatric endocrinologist and if it does not cost more than the least costly somatropin.